The market didn't react positively to the diagnostics specialist's third-quarter earnings report. It beat on both the top and bottom lines, but growth rates were low. Bio-Rad's Q3 saw the company book ...

We recently compiled a list of the 7 Best Medical Technology Stocks To Buy According To Analysts. In this article, we are going to take a look at where Bio-Rad Laboratories, Inc. (NYSE:BIO) stands ...

Longleaf Partners, managed by Southeastern Asset Management, released its “Partners Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned -5.14% in ...

HERCULES, Calif. - Bio-Rad Laboratories, Inc. (NYSE:BIO) reported fourth-quarter results that fell short of analyst expectations, sending shares down 4% in after-hours trading Thursday. The life ...

Bio-Rad Laboratories (NYSE:BIO) is set to give its latest quarterly earnings report on Thursday, 2025-05-01. Here's what investors need to know before the announcement. Analysts estimate that Bio-Rad ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) reported better-than-expected second-quarter financial results on Thursday. Bio-Rad Laboratories reported quarterly earnings of $2.61 per share which beat the ...

BIO-RAD LABORATORIES ($BIO) posted quarterly earnings results on Thursday, February 13th. The company reported earnings of $2.90 per share, beating estimates of $2.90 ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) is scheduled to announce Q3 earnings results on Wednesday, October 29th, after market close. The consensus EPS Estimate is $1.93 (-4.0% Y/Y) and the consensus ...

Bio-Rad Laboratories, Inc. BIO posted third-quarter 2025 adjusted earnings per share (EPS) of $2.26, which missed the Zacks Consensus Estimate by 1.74%. However, the bottom line increased 11.9% from ...